Submit PA for non‑formulary drugs

Providers must complete and submit the Ambetter Prior Authorization form for non‑formulary drug requests; urgent requests will be answered within 24 hours and non‑urgent requests within 72 hours after all required information is received.

• Submit the completed Prior Authorization form to Ambetter.
• Expect response: urgent = 24 hours; non‑urgent = 72 hours (unless state law requires faster).

Obtain PA for specialty/biologic agents

Many biologic and specialty agents listed on the formulary (for example multiple ADALIMUMAB presentations, ACTEMRA, ENBREL) are annotated with 'PA' and require prior authorization before coverage will be provided.

• Obtain PA prior to dispensing for biologic/specialty products shown with 'PA'.
• Package/quantity limits (e.g., package(s) per 180 days) may be enforced with PA requests.

PA required for opioid entries

Opioid-containing products and many analgesic entries show PA or new‑start constraints; where 'PA' is indicated, providers must secure prior authorization before coverage.

• New opioid starts are limited to a 7‑day supply unless authorized (see new‑start limits).
• If a listed opioid shows 'PA' obtain prior authorization before dispensing.

Get PA when 'PA' flag or max‑fill shown

Products explicitly annotated with 'PA' (and any shown maximum‑fill language) require prior authorization before the payer will provide coverage for that item.

• Check the formulary line for 'PA' or 'SP; PA' and obtain PA prior to dispensing.
• Observe any max‑fill or per‑period limits when preparing PA documentation.

Request PA for listed high‑cost/specialty products

Selected high‑cost or specialty agents in the list (examples include enoxaparin presentations, NAYZILAM, VALTOCO, SPRAVATO) are flagged 'PA' — providers must request prior authorization for these products.

• Confirm PA requirement on the specific product line (e.g., enoxaparin strengths, NAYZILAM, SPRAVATO).
• Do not dispense expecting coverage without approved PA.

Obtain PA for items marked 'PA' or 'SP; PA'

Multiple drugs and drug groups are designated 'PA' or 'SP; PA' (specialty + prior authorization); providers must obtain the required prior authorization before dispensing those items.

• When an entry shows 'SP; PA' route the request to the specialty channel and obtain PA.
• Confirm PA is approved prior to patient administration or pharmacy claim submission.

Do not dispense without PA when 'PA' shown

Any formulary entry that shows 'PA' requires prior authorization from Ambetter before coverage — providers must secure approval prior to dispensing the medication.

• Verify the product line for a 'PA' marker and obtain authorization prior to supply.
• Claims submitted without required PA may be denied.

Obtain PA for products with 'PA' noted

Many formulary lines include 'PA' next to the drug/strength (e.g., asenapine maleate and other example entries); obtain prior authorization as indicated on the product line.

• Check the specific strength/packaging line for PA notation.
• Provide PA approval before submitting pharmacy claims for those strengths.

Use specialty channel and obtain PA for 'SP; PA' items

Specialty products annotated 'SP; PA' require both specialty routing and prior authorization (example: FUZEON listed as 'SP; PA').

• Submit PA and ensure specialty pharmacy fulfillment where 'SP; PA' is shown.
• Coordinate with the specialty network per Ambetter guidance before dispensing.

PA required for SOFOSBUVIR‑VELPATASVIR

SOFOSBUVIR‑VELPATASVIR tablets are listed with 'PA' — providers must request prior authorization for hepatitis C treatment with this agent.

• Include clinical documentation supporting the hepatitis C indication when submitting PA for SOFOSBUVIR‑VELPATASVIR.
• Do not assume coverage without approved PA.

Secure PA for specialty pulmonary hypertension drugs

Several pulmonary hypertension and specialty pulmonary agents (e.g., treprostinil, epoprostenol, TYVASO kits, sildenafil/tadalafil PH products) are annotated with 'PA' or 'SP; PA' — obtain prior authorization before dispensing.

• Submit PA and supporting clinical documentation for pulmonary hypertension agents marked 'PA' or 'SP; PA'.
• Products with 'SP' may require specialty fulfillment in addition to PA.

Request PA for listed topical/systemic products

Certain topical and systemic dermatologic products (for example halobetasol‑related entries, isotretinoin, tacrolimus) list 'PA' — providers must request prior authorization for those formulations when indicated.

• Verify product line for PA and age limits (e.g., isotretinoin: AL(At least 12 yrs old) and PA).
• Include patient age and indication in PA submission for topical immunomodulators and tacrolimus.

Obtain PA for topical agents with 'PA'

Some topical agents such as halobetasol formulations and others are annotated with 'PA' on the formulary — obtain prior authorization when the product line indicates PA.

• Confirm the exact formulation/strength line for the PA annotation before prescribing.
• Provide required documentation with the PA request (age, indication, previous therapy as applicable).

Follow step therapy where 'ST' applies

Step therapy (ST) may apply to some products; the formulary indicates that, in applicable cases, a specified alternative must be tried before Ambetter will cover the requested agent.

• If 'ST' appears on the product line follow the step requirement (trial of preferred alternative) before requesting PA for the subsequent agent.
• Document prior trials when submitting an authorization if step therapy is applicable.

Document trial of ibuprofen for ACTEMRA (ST)

Example: ACTEMRA SOLN notes 'Must try ibuprofen: ST' — providers must document a trial of ibuprofen before the step requirement is satisfied for ACTEMRA.

• Document prior trial of ibuprofen when requesting coverage for ACTEMRA SOLN as indicated by the 'ST' note.
• Include trial duration and response in the PA/step documentation.

Comply with starter‑pack and 'SP' constraints

Some products are labeled 'SP' or appear as starter packs (e.g., ELIQUIS starter pack), indicating restricted distribution or starter‑pack rules; follow the indicated channeling/pack constraints when prescribing.

• Route starter packs or SP‑designated products through the specialty/pharmacy channel noted by the formulary.
• Observe per‑period max fill language (e.g., 1 max fill per 180 days for starter packs) when dispensing.

Use tiering to guide preferred choices

Therapeutic class tiering and tier assignments imply preferred agents (tiers 1A/1B/2/3/4); though explicit step algorithms are not provided, use tiering to guide preferred prescribing.

• When no explicit 'ST' is shown, prefer lower‑tier agents consistent with benefit design.
• If a higher‑tier agent is requested, be prepared to document prior trials or obtain PA if required.

Tiering suggests preferred agents

Tier assignments imply preferred status (lower tiers preferred); providers should consider lower‑tier alternatives first though the excerpt does not list full step rules.

• Check the product's tier before prescribing; choose lower‑tier options when clinically appropriate.
• If prescribing higher‑tier drugs, expect potential PA or justification requirements.

Adhere to 'ST' when shown

Where a product line shows 'ST' (step therapy), such as for some antiparkinson agents, providers must follow the step requirement (trial of the specified alternative) prior to approval.

• Document the required prior therapy when submitting an authorization for agents marked 'ST'.
• Failure to document prior trial may lead to denial or request for additional information.

No explicit step algorithm in excerpt — follow tiers and PA

The excerpt does not provide a complete step‑therapy algorithm; when 'ST' is not specified, follow documented tier preference and PA processes.

• If no explicit step sequence is listed, rely on tier preference and be prepared to provide prior therapy documentation if PA is requested.
• Consult full policy or pharmacy helpdesk for complete step therapy rules if uncertain.

Step therapy details not specified here — verify with payer

No explicit step therapy sequencing text is included in this extract; providers must refer to product lines for any 'ST' flags and to the payer for full step policy details.

• When 'ST' is shown on a product line, include documentation of prior trial(s) with the PA or step submission.
• Contact Ambetter for the complete step‑therapy algorithm if needed.

Follow 'ST' for listed topical products

Step therapy applies to specified products in the extract (examples include clindamycin/tretinoin and multiple corticosteroid entries marked 'ST'); follow the step requirement where shown.

• Document prior use of required alternative agents when requesting authorization for 'ST'‑flagged topical products.
• Include age and prior treatment details as required.

Tiering implies preference; verify 'ST' where applicable

Tier assignments imply preferred agents but do not replace explicit step requirements; verify 'ST' flags on product lines when applicable.

• If a product is higher tier, expect PA or step documentation may be required.
• Confirm any 'ST' note on the exact formulation line before submitting PA.

Submit PA with required documentation; note 24/72‑hour turnarounds

Providers must complete the Prior Authorization form and submit necessary clinical information; urgent requests will be answered within 24 hours and non‑urgent within 72 hours once all information is received.

• Submit completed PA form with supporting clinical documentation to avoid delays.
• Expect disapproval notices to state reasons or identify missing material information if the request is incomplete.

Document prior fills and package/fill‑intervals for PA requests

Formulary entries show quantity limits and package/fill‑interval language (e.g., package(s) per 180 days) — providers should document fill history and relevant dispensing intervals when submitting PA.

• Include prior fill history and justification when requesting exceptions to package or per‑period limits.
• Reference the exact per‑period limits from the product line in the PA request.

Document justification when requesting >7‑day opioid supply

When requesting authorization for opioid prescriptions exceeding new‑start limits, prescribers should document clinical justification for longer supplies — new starts are limited to a 7‑day supply per the formulary.

• Document rationale and prior therapy when requesting PA for opioid supplies beyond the 7‑day new‑start limit.
• Be aware policy permits up to two 7‑day fills in any 28‑day period and up to 28 non‑consecutive days in 90 days (per thresholds).

Include clinical justification for PA requests that seek QL overrides

Many product entries pair PA or SP flags with quantity limits (QL); when PA/QL are shown, include clinical justification for the requested quantity and dose in the PA submission.

• Provide diagnosis, prior therapies, and rationale for requested quantity when submitting PA for QL‑restricted products.
• Ensure claims reflect the QL/PA annotations to avoid rejection.

Ensure claims reflect QL and PA on approved authorizations

Pharmacy claims must reflect the formulary's QL and PA indicators; providers should ensure claim submissions include authorization identifiers and match the approved quantity/intervals.

• Include the PA approval number on the claim and adhere to approved quantity limits.
• Claims with quantities exceeding QL or missing required PA may be denied.

Document patient age and indication for AL‑restricted drugs

When a product has an Age Limit (AL) shown (for example isotretinoin, XIFAXAN entries), providers must document the patient's age and indication in the PA or claim.

• Include patient age and the clinical indication in the PA request for AL‑restricted products.
• Verify member meets the AL before dispensing or submitting the claim.

Provide supporting clinical documentation for PA/QL requests

For PA or QL requests, providers must supply supporting clinical documentation that justifies the requested quantity or dose (for example prior treatment history or clinical rationale).

• Attach prior therapy records, relevant labs, and treatment rationale to the PA submission.
• Insufficient documentation may lead to disapproval or request for additional information.

Document fill‑intervals when requesting QL exceptions

Quantity limits and fill‑interval language are enforced (examples: 1 max fill per 90/180 days, QL per fill/period); providers should document dispensing intervals when requesting exceptions or PA.

• Cite prior fill dates and quantities when asking for exceptions to max‑fill rules.
• Use the formulary's stated per‑period limits in the PA justification.

Provide documentation for SP/PA injectable products

Specialty (SP) and PA flags on injectable or infusion products indicate restricted distribution and require supporting documentation with PA submissions and routing through specialty channels as indicated.

• When 'SP' appears, coordinate with the specialty pharmacy network and include necessary supporting documents with the PA.
• Some infusion/injectable products require both SP routing and PA prior to coverage.

Document age and quantity compliance for AL/QL products

Age and quantity limits are enforced for multiple products (examples: pimecrolimus AL(At least 2 yrs); tacrolimus OINT AL + PA); providers must document age and QL compliance in PA requests.

• Confirm patient meets AL before submitting PA or dispensing.
• Include age and prior treatment details in the PA when AL or QL is listed.

Expect specific reasons on PA denials

If a prior authorization request is disapproved, the disapproval notice will state specific reasons for the denial or identify missing material information required to complete the request.

• Review the notice to determine whether additional information can cure the denial.
• Submit missing material information promptly when identified.

Claims may be denied for specialty drugs without PA

Claims for specialty agents may be denied if PA is not obtained when indicated (many specialty biologics and injectable products show 'PA' or 'SP; PA').

• Obtain PA prior to dispensing specialty biologics to avoid claim denials.
• Verify specialty routing requirements and PA approval before patient administration.

QL exceedance can trigger denials

Exceeding a product's quantity limit (QL) can trigger denial or require a prior authorization; document prior therapy and justification when requesting quantities beyond the QL.

• Do not submit claims exceeding QL without an approved PA.
• Include relevant clinical rationale and prior use when seeking QL exceptions.

PA/QL/new‑start limits may trigger denials

Entries marked with PA and/or those that exceed quantity or new‑start limits (e.g., new starts limited to 7 days) may trigger denials or require additional review; obtain PA where indicated.

• For new‑start opioid fills beyond 7 days, submit PA with supporting justification.
• If PA is required and not obtained, expect the claim to be denied or returned for review.

Missing PA/SP or exceeding QL risks denial

Formulary flags 'PA', 'SP', and explicit QL or max‑fill per period are common denial triggers — missing required PA or exceeding limits may cause claim denial or noncoverage.

• Before dispensing, verify whether the product line shows 'PA' or 'SP' and obtain approvals.
• Confirm the dispensed quantity and fill interval conform to formulary limits to avoid denials.

Obtain PA for enoxaparin strengths showing 'PA'

Multiple enoxaparin presentations are annotated with 'PA' — providers should obtain prior authorization for the listed enoxaparin strengths to avoid coverage denial.

• Check the exact enoxaparin strength/format for a 'PA' notation and secure authorization before dispensing.
• Claims for enoxaparin may be denied if PA is not in place.

Secure PA for CNS/rescue agents flagged 'PA'

Several CNS/rescue medications (examples: NAYZILAM, VALTOCO, SPRAVATO) are flagged with 'PA' — dispensing without prior authorization risks claim denial.

• Verify PA is approved before dispensing NAYZILAM, VALTOCO, or SPRAVATO formulations that show 'PA'.
• Include quantity limit compliance and indication in the PA to reduce denial risk.

PA or SP; PA markers require prior authorization

Formulary entries that display 'PA' or 'SP; PA' indicate prior authorization or specialty prior authorization requirements; failure to obtain required authorization may lead to claim denial.

• When the product line shows 'PA' or 'SP; PA', do not assume coverage without documented authorization.
• Follow specialty routing and documentation procedures for SP; PA items.

QLs are enforceable — request PA for exceedance

Quantity limits shown on product lines (examples: QL(4 EA daily; 40 EA per fill), QL(3 EA daily)) are enforceable utilization limits — requests exceeding these limits require PA or may be denied.

• Review the product's QL before prescribing and document justification when seeking exceedance.
• Include prior dispensing records in PA to support requests above QL.

Missing PA/SP may lead to denials

If PA or specialty pharmacy requirements are not met for products that list 'PA' or 'SP; PA', requests may be denied — verify and obtain necessary approvals prior to dispensing.

• Confirm and document PA/SP requirements on the exact product line before filling.
• Denials for missing PA/SP can be appealed with supporting clinical information if appropriate.

Route specialty‑tier drugs to participating specialty/hemophilia pharmacies

Some infusion/ specialty‑tier drugs must be fulfilled at participating specialty or hemophilia network pharmacies; providers should route such prescriptions accordingly.

• Use Ambetter's specialty/hemophilia network for fulfillment when the product is specialty‑tier.
• Check Ambetter pharmacy information for network participation.

Coordinate PA and specialty handling for injectable/infusion products

Injectable/infusion products marked 'PA' and 'SP' indicate restricted distribution or specialty handling; obtain PA and coordinate specialty fulfillment before administration.

• Coordinate PA approval with the specialty pharmacy and confirm handling/fulfillment requirements.
• Do not schedule infusion/administration until PA and specialty routing are confirmed.